Public Companies
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
Cybin Inc. (NEO:CYBN | NYSE American:CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to announce…
Cybin Inc. (NEO:CYBN | NYSE American:CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to announce its participation in the following upcoming investor events:
Jefferies London Healthcare Conference, November 15-17, 2022
- Doug Drysdale, Cybin’s Chief Executive Officer, will present on November 15, 2022 at 8:00 a.m. GMT and host investor meetings. To listen to the presentation, please click here to register and access the webcast.
Pinsent Masons Psychedelics Panel, November 16, 2022, in London, UK
- Mr. Drysdale will participate in a panel discussion titled “Psychedelics Landscape – What can we expect?” at 5:00 p.m. GMT. To listen to the panel, please click here to register and access the webcast.
PSYCH Investor Event: Emerging Innovations in Psychedelic Healthcare, November 17, 2022, in London, UK
- Mr. Drysdale will participate in a live fireside chat at 5:00 p.m. GMT with other industry thought leaders.
About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
-
Psychedelics1 week agoExploring Psilocybin’s Potential in Diabetes Management
-
Psychedelics1 week agoAll About the New Ketamine Trial at the University of Otago
-
Psychedelics1 week agoCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Law & Regulation1 week ago
Canada’s Optimi Health to ship psilocybin to New Zealand psychedelics research center
-
Law & Regulation1 week agoSynaptogenix increases psilocybin stake with PsygaBio
-
Psychedelics1 week agoThe EU’s Plan for a €6.5M Study of Psychedelics To Treat Mental Disorders
-
Psychedelics1 week ago
Exploring Psilocybin’s Potential in Diabetes Management
-
Psychedelics1 week ago
The EU’s Plan for a €6.5M Study of Psychedelics To Treat Mental Disorders
